Subscribe
money_istock-504240346_jansucko
jansucko / iStockphoto.com
2 November 2017Americas

Valeant pays $13m in royalty settlement

Canada-based Valeant has agreed to pay $13 million to biotechnology company PDL BioPharma to settle a dispute over royalties.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Neos Therapeutics sues Teva and Actavis
2 September 2016   Neos Therapeutics has filed a patent infringement suit against Teva, and its subsidiary Actavis, for allegedly infringing a number of its patents.
Americas
Valeant agrees to license Acanya in Actavis settlement
13 May 2014   Canadian pharmaceutical company Valeant announced yesterday (May 12) that it had settled all litigation related to its acne treatment Acanya (clindamycin phosphate and benzoyl peroxide) with Actavis.


Editor's picks

UKIPO rejects Boehringer’s SPC for horse inhaler
Americas
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

Editor's picks

Americas
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Americas
Neos Therapeutics sues Teva and Actavis
2 September 2016   Neos Therapeutics has filed a patent infringement suit against Teva, and its subsidiary Actavis, for allegedly infringing a number of its patents.
Americas
Valeant agrees to license Acanya in Actavis settlement
13 May 2014   Canadian pharmaceutical company Valeant announced yesterday (May 12) that it had settled all litigation related to its acne treatment Acanya (clindamycin phosphate and benzoyl peroxide) with Actavis.

More on this story

Americas
Neos Therapeutics sues Teva and Actavis
2 September 2016   Neos Therapeutics has filed a patent infringement suit against Teva, and its subsidiary Actavis, for allegedly infringing a number of its patents.
Americas
Valeant agrees to license Acanya in Actavis settlement
13 May 2014   Canadian pharmaceutical company Valeant announced yesterday (May 12) that it had settled all litigation related to its acne treatment Acanya (clindamycin phosphate and benzoyl peroxide) with Actavis.

More features

UKIPO rejects Boehringer’s SPC for horse inhaler
WilmerHale gains partner with ‘deep expertise’
Bayer, Orion take on Indian generic over $117bn drug
‘We created law’: G1/24 and the creation of the ‘diamond standard’
BMS unit loses cell therapy patent at European Patent Office
Amgen sues Biocon over blockbuster bone drugs as first biosimilars enter market
Lord Justice Birss to become chancellor of the High Court
Bankruptcy judge approves $305m sale of genetics testing company